Search This Blog

Tuesday, November 3, 2015

Amgen To Highlight Cardiovascular Portfolio At American Heart Association Scientific Sessions 2015

Repatha™ (Evolocumab) Data Analysis Examines Effect of Dosing on LDL-C Reduction and Duration of Response
Corlanor® (Ivabradine) Session Features Post-Hoc Safety Analysis of Continued Treatment in Patients Hospitalized With Worsening Heart Failure


Amgen - Investors - RSS Content
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)